Medicine C Flashcards
(172 cards)
What is frailty?
This is not about age but is more common in older people. It is often associated with being underweight, but this is also not true.
Frailty is defined as a physiological syndrome characterised by a decreased reserve and diminished resistance to stressors, resulting from cumulative decline across multiple physiological systems, and causing vulnerability to adverse outcomes.
What are the symptoms of frailty?
Symptoms of frailty can include mobility problems, falls, confusion, and incontinence. These can be caused by any illness such as respiratory tract infections. Frailty syndromes are not specific diseases and can present with a variety of symptoms. They can have any cause but are more likely with multiple impairments. Therefore, patients should be provided with a bespoke treatment plan following an MDT approach.
What are the 4 themes for identifying frailty?
- Cumulative impairment methods – CSHA 70 point score of multimorbidity. This refers to the ‘Jenga theory’ of removing important functions to cause overall collapse. These are the GOLD standard for frailty assessment.
- Phenotypical measures: The Freid et al model uses weight, hand grip weakness, exhaustion, slowness of walking speed and low physical activity level. This provides a quantitively result for research but is limited for cognitive impairment and severe frailty.
- Surrogates: The Bournemouth criteria determines who is eligible for the frailty service. Anyone aged over 90 is eligible. Otherwise patients aged 75-89 with 2 of the following: Immobility, incontinence, instability, intellectual impairment or iatrogenesis (polypharmacy over 5 medications). It will also be given to those over 65 who reside in a nursing or residential home.
- The Clinical Frail Scale is a descriptor method. It is all about the baseline and can only be used in over 65s. If someone has a terminal illness, they are CSF 9 because there is an expected deterioration. This score can be used in patients with dementia.
What are the implications of frailty?
Frailty has a dramatic impact on mortality. There is an increased risk of hip fracture, hospitalisation, ED admission, and poorer outcomes in renal transplant/general surgery/cardiac interventions.
What is a comprehensive geriatric assessment?
Comprehensive geriatric assessment is a multi-professional holistic assessment of a patient and must be patient centred. It include assessment of domains of health and the aim is to formulate a bespoke individual care plan.
CGA is done in response to age or efrailty scoring. Other indications for CGA are acute illness, high healthcare utilisation, change in circumstances, frailty syndromes and chronic disease. The care plan should then be implemented, monitored and further MDTs may be needed to revise a care plan.
Physical assessment should identify any acute illness, chronic illness, pain, nutrition status and assess continence. Gait and balance should be assessed somewhere that the patient knows well (home) and should also include footware assessment and lying/standing BP. Functions (ADLs) and sensory loss should also be assessed.
Psychological assessment should include mood assessment, sleeping, suicidal ideation, drugs, alcohol, depression, grief, loneliness, and cognitive assessment.
Social assessment includes support which may be beneficial, maintaining independence, beware of overprescribing, environmental assessment and telecare (falls alert technology).
Medication review is essential as polypharmacy is linked with poor concordance, increased risk of interactions, increased risk of falls, and cognitive decline so the benefits and risks should be weighed up. Beware of the prescribing cascade. Review medication indications.
Therefore, the CGA brings together these assessments to create a care plan. This should be a multifactorial plan for all domains and a schedule for monitoring and review should be established for each element.
What is an advanced care plan vs an anticipatory care plan?
ACP is an advanced care plan. These are usually put in place to refuse a future potential treatment such as ventilation. It must be in writing and state ‘even if life is at risk’ to refuse life prolonging treatment.
AnCP is an anticipatory care plan and is not an end-of-life plan. They are designed to reduce the risk to the patient by anticipating medical crises and planning a response.
Who can implement a DNACPR?
DNACPR is a medical decision. Patients cannot demand CPR is it is deemed to inappropriate but there is a legal requirement to inform the patient if a DNACPR is put in place.
Describe some common lung conditions on post mortem
In lobar pneumonia there is complete consolidation of an entire lobe with sparing of the other lobes. In Bronchopneumonia the consolidation follows the airways from the main bronchus.
Lobar pneumonia is much less common than bronchopneumonia and is predominantly caused by streptococcus pneumoniae. Severe pneumococcal pneumonia has a mortality around 20%.
Empyema will have pus like exudate with granulation tissue growing into the pleura and pus in the pleural space. It is often a continuation of a pneumonia but can occur spontaneously.
Abscessing bronchopneumonia is where the pus-filled space is in the lung parenchyma following pneumonia.
In aspiration pneumonia the airways are not filled by inflammatory cells but they are present in the interstitium between alveoli. This is then expanded by chronic inflammatory infiltrate which includes multinucleated giant cells which respond to the presence of foreign bodies.
Viral pneumonia does not have airways filled with inflammatory cells but there is infiltration by lymphocytes in the interstitium. COVID causes clotting instead. Viral pneumonia can be caused by influenza A and B, parainfluenza, adenovirus, human metapneumovirus and RSV (mainly children but can affect the eldery). Cytomegalovirus can appear in immunocompromised.
Bronchiectasis is peripheral airways becoming enlarged and cartilaginous due to repeated cycles of infection. This is due to inability to clear secretions from motility disorders, cystic fibrosis, localised established infection and mechanical obstruction such as a tumour.
Chronic bronchitis is a clinical diagnosis and not a pathological diagnosis. COPD is also a combination of chronic bronchitis and emphysema. They will have large emphysematous spaces in the lung. There will be half as many air spaces because the spaces have become enlarged.
Fibrous plaques form in the pleura and are associated with asbestos exposure. They are usually picked up on imaging. They do not cause harm themselves. It takes decades for asbestos pathology to present. Asbestos can cause interstitial lung disease but it is best known for increasing risk of malignancy, especially mesothelioma.
Honeycomb lung is seen in interstitial fibrosis occurring as the end stage of interstitial lung diseases. These are completely non-functioning lung.
Diffuse alveolar damage is an interstitial change pathological caused by acute respiratory distress syndrome. This is why there is white out of both lungs because the lung tissue has been replaced with fibrous tissue. It has a very high mortality.
What are the presentations of bowel conditions post-mortem?
Diverticuli are very common in elderly patients (around 60%). BPH is also extremely common.
Pathology of small bowel ischaemia and atherosclerosis were also discussed in this lecture. Know the presentation of these syndromes in the elderly for the exam!!!
Pseudomembranous colitis is caused by c.difficile . Patients on long term antibiotics develop this. The neutrophils cause the volcanic appearance of the pseudomembrane.
How does GORD cause Barrett’s?
GORD causes obliteration of the gastro-oesophageal junction. This is caused by Barrett’s like changes.
When should a renal biopsy be done?
Purpose is to establish a tissue diagnosis, assess the severity/activity of disease, or to assess the amount of irreversible damage/tubular atrophy/glomerular sclerosis. 7-10 glomeruli need to be taken for an adequate reading without damaging the kidney. It is important that the site of biopsy is noted as subcapsular biopsies have a tendency to overestimate the global sclerosis related to ageing, hypertension or non-specific scarring.
How are renal biopsy findings described?
Focal glomerular changes: Under 50% of the glomeruli are affected
Diffuse glomerular changes: Over 50% of the glomeruli are affected
Segmental glomerular changes: involving part of the glomerular tuft of a single glomerulus
Global glomerular changes: Involving all of the glomerular tuft of a single glomerulus
Acute lesions: Usually means recent and reversible damage such as glomerular proliferation, interstitial inflammation, and acute tubular necrosis
Chronic lesions: Irreversible damage such as glomerulosclerosis, interstitial fibrosis and tubular atrophy.
What are the classifications of acute renal failure?
This can be divided into three clinical patterns:
1. Pre-renal
2. Renal/intrinsic
3. Post-renal
Describe pre-renal causes of AKI
Pre-Renal is caused by decreased renal perfusion. Causes can include heart failure, volume loss (D+V, burns, internal or external haemorrhage), or systemic arteriolar vasoconstriction (NSAIDs and radiocontrast). Biopsy should not be performed when pre-renal is suspected.
If a biopsy is taken there will be non-specific findings but the general effect of hypoxia or ischaemia. There may be acute tubular necrosis (reversible) or partial collapse of glomeruli. On histology there will be swelling of the cytoplasm, eosinophilia, vacuolation and loss of nuclei. The collapse of glomeruli is also reversible and visible on histology.
What are the glomerular (renal) causes of AKI?
Glomerular: Glomerulonephritis can cause acute renal failure and usually falls into a class referred to as a rapidly progressive glomerulonephritis (RPGN) or crescentic glomerulonephritis. The pathologic feature of RPGN is the prescence of glomerular crescents. This is reversible.
Crescents can be cellular, fibrocellular, or fibrous depending on their composition. They are caused by the proliferation of parietal epithelial cells in response to an injury that breaks the capillary wall which can then be associated with necrosis. The aetiology can be autoimmune (Anti-GBM, IgA or MGM) or immune complex modulated (ANCA associated vasculitis).
What are the vascular (renal) causes of AKI?
: Large vessel obstruction such as renal artery (thrombosis, emboli or dissection) or renal vein (thrombosis). Small vessels can also caused ARF (Haemolytic uraemic syndrome, DIC, and pre-eclampsia) and malignant hypertension will affect the kidneys.
Cholesterol emboli are common causes of unexplained ARF in elderly patients. Predisposing factors include trauma, surgery, and anticoagulation. This may be slowly progressive and involve the glomeruli. Pre-eclampsia on histology will show endothelial swelling which causes an obstruction, this is reversible damage. Infraction is irreversible damage. Microangiopathy will have micro-thrombi filling the glomeruli capillary lumens and hence renal ARF.
Malignant hypertension presents on histology with intimal proliferation of spindle cells in the walls of the arteries and hence lumen obstruction. This shows as an onion skin appearance. This is reversible so the aim is to improve their blood pressure and prevent the development of fibrous tissue.
What are the tubular (renal) causes of AKI?
The most common cause of tubular ARF is ischaemic or cytotoxic acute tubular injury. Frank necrosis is not prominent in most cases of ATN and tends to be patchy. Cytotoxic events include rhabdomyolysis (remember cocaine can cause this), lithium, NSAIDs and radiocontrast agents.
On histology, rhabdomyolysis will show myoglobin blockage causing ATN. This can be reversible. The timing of the biopsy is important as only early on will the specialist staining for myoglobin pick anything up.
What are the interstitial (renal) causes of AKI?
The main cause of this is inflammation otherwise known as tubulointerstitial nephritis. This can be caused by drugs (penicillin, NSAIDs), infection (pyelonephritis), and systemic disease (sarcoidosis, lymphoma, and leukemia). There will be inflammatory infiltration on histology.
Tubular interstitial necrosis is a non-specific diagnosis and an underlying cause should be sought:
- Intratubular polymorphonuclear neutrophils forming plugs are diagnostic of acute pyelonephritis
- Eosinophils in the interstitium can indicate a drug reaction
- Granulomas can indicate a drug reaction. Confluent granulomas point to sarcoidosis whereas necrotising granulomas are indicative of infection (especially TB or fungus)
Deposition of casts is most commonly oxalate in oxalosis (primary or secondary such as ethylene glycol ingestion or jejunal interstitial bypass). On histology they appear like shining glass because they are reflecting the light back at the microscope.
What are the post-renal causes of AKI?
Post-renal causes include urinary tract obstruction which increases the intra-tubular pressure and thus decreases GFR. Acute obstruction can also lead to impairment of the renal blood flow and inflammatory reaction which will further diminish GFR/ Obstruction of the urinary tract at any level can produce AKI. Treatment is to manage the cause.
Which systemic diseases can cause AKI?
Diabetic nephropathy, papillary necrosis, systemic hypertension, amyloidosis, and multiple myeloma.
How does AKI develop in renal failure?
- Acute cellular mediated rejection
- Acute antibody mediated rejection
- Acute ischaemic injury/acute tubular damage
- Calcineurin inhibitor nephrotoxicity (cyclosporine and tacrolimus)
- Major artery/vein thrombosis
- Renal artery stenosis
- Obstruction
- Infection
- Acute tubule-interstitial nephritis (drug allergy)
- Recurrent primary disease
What is CKD and what are the most common causes?
Chronic renal failure is caused by a progressive decline in all kidney functions, ending in terminal kidney damage. The most common causes are diabetic nephropathy, hypertensive nephropathy, primary glomerulonephritis, TIN, and recurrent infection.
There is a reduction in nephron numbers, hyper-filtration of remaining nephrons (glomerular enlargement), proteinuria and HTN, acute tubular damage, inflammation, segmental glomerulosclerosis, interstitial fibrosis, and tubular atrophy which further reduces nephron numbers.
How does renal impairment impact pharmacotherapy?
Drugs are generally excreted in the kidneys, and this occurs in a variety of ways. Most drugs have a component of renal excretion. Drugs are generally filtered into the bowman’s capsule, and this is dependent on renal blood flow and glomerular filtration rate. Drugs that are protein bound will not be filtered as they are too large to move into the capsule.
Secretion occurs when a drug has a specific mechanism that allows transport into the kidney tubule, usually the proximal tubule. The two main transporters involved in this process which are the OAT transporter which transports organic anions and the OCT transporter which transports organic cations. These are an important mechanism for drugs which are protein bound.
Reabsorption mainly occurs in the distal tubule. The drugs which are more likely to be reabsorbed are lipophilic which enables them to pass through the epithelial aspects of the tubule and into the bloodstream. The polarity of drugs and metabolites is affected by the urine pH and that may affect their ability to diffuse across those membranes.
Patient factors mainly impact filtration. Renal impairment is defined as AKI or CKD.
The KDIGO classification for AKI
The KDIGO classification of chronic kidney disease
Renal impairment impacts the renal handling of drugs. Patients with CKD are more susceptible to side effects and tolerate them poorly. In terms of pharmacokinetic effects there is reduced renal clearance which leads to higher steady-state concentrations. For drugs with a narrow therapeutic index this may lead to toxicity. The most important drugs in this context are those with a high proportion of renal clearance (the fraction excreted unchanged) and a narrow therapeutic index.
The pharmacodynamic effects include sensitivity to some drugs being increased by renal impairment and some drug effects may be attenuated by renal impairment.
How does hepatic impairment impact pharmacotherapy?
The liver is the main site of drug metabolism as it is involved in the conversion of the active, lipid soluble drug to inactive hydrophilic metabolites. (Codeine to morphine). This generally results in detoxification and elimination. Sometimes metabolism is required to convert a pro-drug to an active form. The liver is exceptionally important for protein bound drugs such as phenytoin and prednisolone. Biliary excretion is not a major route for drug elimination, but important for some such as rifampicin and fusidic acid.
Reduced metabolism in severe liver disease cannot be determined from routine LFTs. It is most likely in parenchymal liver disease (hepatitis or alcohol) because the liver has a huge hepatic reserve so can usually compensate before hepatic impairment causes reduced metabolism. This causes a slower metabolism of the parent compound and hence reduced clearance rate, elevation of serum concentration of the parent compound, leads to increased and prolonged drug effect, increased risk of adverse drug reactions, especially for drugs with a narrow therapeutic index, increased risk of drug-drug interactions and reduced efficacy or pro-drugs (codeine). Further, there is a serious risk of overdose on morphine due to reduced first-pass metabolism of drugs which high hepatic extraction.
The reduced protein production means lower circulating albumin levels. This means reduced protein binding of drugs, increased proportion of free drug and thus increased receptor-binding/drug effect/toxicity (phenytoin and prednisolone).
The reduction of clotting factors causes prolonged prothrombin time and thus increased sensitivity to oral anticoagulants (warfarin).
Reduced biliary excretion is found in cholestatic liver disease such as primary biliary cirrhosis. This leads to reduced biliary excretion and accumulation of those drugs with major elimination by this route as seen in rifampicin and fusidic acid.
Hepatic encephalopathy can be worsened or caused by drugs including sedatives, opioids, diuretics producing hypokalaemia, and constipating drugs. Fluid overload may also be exacerbated by drugs that promote fluid retention (NSAIDs and corticosteroids) and when there is fluid overload a higher dose of digoxin may be needed to reach therapeutic range. Hepatotoxity is a feature of many medications which can be dose dependent or idiosyncratic (unpredictable hepatic toxicity).